Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP

The combination of KRAS G12C inhibitors with EGFR inhibitors has reproducibly been shown to be beneficial. Here, we identify another benefit of this combination: it effectively inhibits both wild-type and mutant RAS. We believe that targeting both mutant and wild-type RAS helps explain why this comb...

Descripción completa

Detalles Bibliográficos
Autores principales: McFall, Thomas, Trogdon, Michael, Guizar, Anita C., Langenheim, John F., Sisk-Hackworth, Laura, Stites, Edward C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684405/
https://www.ncbi.nlm.nih.gov/pubmed/36418474
http://dx.doi.org/10.1038/s41698-022-00329-w
Descripción
Sumario:The combination of KRAS G12C inhibitors with EGFR inhibitors has reproducibly been shown to be beneficial. Here, we identify another benefit of this combination: it effectively inhibits both wild-type and mutant RAS. We believe that targeting both mutant and wild-type RAS helps explain why this combination of inhibitors is effective.

Ejemplares similares